PropertyValue
is ?:annotates of
?:authorAffiliation
  • [\'Santé publique France, Direction des régions, Occitanie, Toulouse, France.\', \'Santé publique France, Direction des maladies infectieuses, Saint-Maurice, France.\', \'Santé publique France, Direction appui traitements et analyses des données, Saint-Maurice, France.\', \'Agence régionale de Santé Occitanie, délégation départementale Pyrénées Orientales, Perpignan, France.\', \'Infectious and Tropical Diseases Department, Perpignan Hospital Center, Perpignan, France.\', \'Laboratory of Biochemistry and Biology, Perpignan Hospital Center, Perpignan, France.\', \'Santé publique France, Direction des régions, Occitanie, Toulouse, France damien.mouly@santepubliquefrance.fr.\']
?:citedBy
  • -1
?:creator
?:doi
?:doi
  • 10.1136/bmjopen-2021-053201
?:hasPublicationType
?:journal
  • BMJ open
is ?:pmid of
?:pmid
?:pmid
  • 34815286
?:publication_isRelatedTo_Disease
?:rankingScore_SJR
  • 1.372
?:rankingScore_hIndex
  • 57
is ?:relation_isRelatedTo_publication of
?:title
  • Seroprevalence of anti-SARS-CoV-2 antibodies after the first wave of the COVID-19 pandemic in a vulnerable population in France: a cross-sectional study.
?:type
?:year
  • 2021

Metadata

Anon_0  
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://purl.org/net/provenance/ns#DataItem>
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://www.w3.org/2004/03/trix/rdfg-1/Graph>
<http://xmlns.com/foaf/0.1/primaryTopic> <https://research.tib.eu/covid-19/entity/34815286>
<http://xmlns.com/foaf/0.1/topic> Anon_0
<http://www.ontologydesignpatterns.org/cp/owl/informationrealization.owl#realizes> <https://research.tib.eu/covid-19/data/entity/34815286>
<http://purl.org/net/provenance/ns#createdBy>
Anon_1   (more)
expand all